Skip to main content
RenovoRx, Inc. logo

RenovoRx, Inc. — Investor Relations & Filings

Ticker · RNXT ISIN · US75989R1077 US Professional, scientific and technical activities
Filings indexed 260 across all filing types
Latest filing 2025-11-10 Major Shareholding Noti…
Country US United States of America
Listing US RNXT

About RenovoRx, Inc.

https://renovorx.com/

RenovoRx, Inc. is a clinical-stage life sciences company developing targeted oncology therapies for solid tumors. The company's core technology is its proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform, which is designed for the localized delivery of therapeutic agents directly to tumors. This approach aims to enhance treatment efficacy while minimizing the systemic toxicities associated with conventional intravenous chemotherapy. The TAMP platform is enabled by the RenovoCath®, an FDA-cleared dual-balloon infusion catheter that isolates blood flow for targeted drug delivery. RenovoRx is advancing its lead drug-device combination product candidate in the Phase III TIGeR-PaC clinical trial for the treatment of locally advanced pancreatic cancer.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-10 English
4
Director's Dealing
2025-10-03 English
Director's Dealing 2025
Director's Dealing
2025-10-03 English
Director's Dealing 2025
Director's Dealing
2025-10-03 English
Director's Dealing 2025
Director's Dealing
2025-10-03 English
Regulatory Filings 2025
Regulatory Filings
2025-08-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.